Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Valeant Pharma (VRX) Outperforms Amid Broad Weakness
May 11, 2017 9:54 AM EDTValeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness
... MoreStifel Comments On Valeant (VRX) Earnings
May 9, 2017 10:25 AM EDTStifel maintains Buy on Valeant Pharmaceuticals (NYSE: VRX) price target of $45.00.
Analyst Annabel Samimy stands out as one of two sell-side analysts who is bullish on the name with a Buy rating. Samimy expects headwinds to persist through the end of 2017 from managed... More
